The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics

Oncology Research

Volumn 16, Issue 11, 2007, Pages 517-525

  Wietrzyk, Joanna ^a   Milczarek, Magdalena ^a   Kutner, Andrzej ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Calcitriol and its analogs; Cisplatin; Combined antitumor therapy; Docetaxel; Imatinib mesylate

Indexed keywords

24A HOMO 1,25 DIHYDROXYERGOCALCIFEROL; CALCITRIOL; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; IMATINIB; PRI 1906; PRI 2191; TACALCITOL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 38949187926     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504007783438330     Document Type: Article

References (40)

1. 3-regulated human keratinocyte proliferation and differentiation: Basic studies and their clinical application. J. Nutr. 125:1709S-1714S; 1995.
2. Waf1/Cip1 in vitro and in vivo. Cancer Res. 59:2644-2649; 1999.
3. 3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J. Dermatol. Sci. 31:21-28; 2003.
4. Johnson, C. S.; Hershberger, P. A.; Bernardi, R. J.; McGuire, T. F.; Trump, D. L. Vitamin D receptor: A potential target for intervention. Urology 60:123-130; 2002.
5. Quack, M.; Carlberg, C. Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements. J. Mol. Biol. 296:743-756; 2000.
6. Reichrath, J.; Rafi, L.; Rech, M.; Mitschele, T.; Meineke, V.; Gartner, B. C.; Tilgen, W.; Holick, M. F. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J. Cutan. Pathol. 31:224-231; 2004.
7. 3 analogue EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 93:745-753; 2001.
8. Alagbala, A. A.; Johnson, C. S.; Trump, D. L.; Posner, G. H.; Foster, B. A. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Oncology 70:483-492; 2006.
9. 3. Anticancer Drugs 18:447-457; 2007.
10. 2 metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res. 25:235-241; 2005.
11. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 78:75-82; 1991.
12. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res. 60:2673-2679; 2000.
13. 3 analogue seocalcitol (EB 1089): Chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg. Med. Chem. 9: 2365-2371; 2001.
14. 2. (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners. Steroids 67:789-798; 2002.
15. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell Biochem. 66:413-425; 1997.
16. Baniahmad, A.; Tsai, M. J. Mechanisms of transcriptional activation by steroid hormone receptors. J. Cell Biochem. 51:151-156; 1993.
17. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837; 1991.
18. Abe-Hashimoto, J.; Kikuchi, T.; Matsumoto, T.; Nishii, Y.; Ogata, E.; Ikeda, K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 53:2534-2537; 1993.
19. Wietrzyk, J.; Pelczynska, M.; Madej, J.; Dzimira, S.; Kusnierczyk, H.; Kutner, A.; Szelejewski, W.; Opolski, A. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 69:629-635; 2004.
20. Siwinska, A.; Opolski, A.; Chrobak, A.; Wietrzyk, J.; Wojdat, E.; Kutner, A.; Szelejewski, W.; Radzikowski, C. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res. 21:1925-1929; 2001.
21. 3 compounds in combination with cytostatics. Anticancer Res. 25:2235-2240; 2005.
22. Opolski, A.; Wietrzyk, J.; Chrobak, A.; Marcinkowska, E.; Wojdat, E.; Kutner, A.; Radzikowski, C. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res. 19:5217-5222; 1999.
23. Opolski, A.; Wietrzyk, J.; Siwinska, A.; Marcinkowska, E.; Chrobak, A.; Radzikowski, C.; Kutner, A. Biological activity in vitro of side-chain modified analogues of calcitriol. Curr. Pharm. Des. 6:755-765; 2000.
24. 3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res. 7:4164-4173; 2001.
25. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 51:2848-2853; 1991.
26. Hershberger, P. A.; Yu, W. D.; Modzelewski, R. A.; Rueger, R. M.; Johnson, C. S.; Trump, D. L. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res. 7:1043-1051; 2001.
27. 3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol. Cancer Ther. 1:821-829; 2002.
28. 3 analogues in breast cancer cells. Cancer Res. 56:2789-2794; 1996.
29. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res. 5:695-703; 1999.
30. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 59:862-867; 1999.
31. 3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int. J. Oncol. 13:421-428; 1998.
32. Beer, T. M.; Hough, K. M.; Garzotto, M.; Lowe, B. A.; Henner, W. D. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin. Oncol. 28:49-55; 2001.
33. Beer, T. M.; Garzotto, M.; Katovic, N. M. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am. J. Clin. Oncol. 27:535-541; 2004.
34. Beer, T. M. ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int. 96:508-513; 2005.
35. Tiffany, N. M.; Ryan, C. W.; Garzotto, M.; Wersinger, E. M.; Beer, T. M. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: A phase I/II study. J. Urol. 174:888-892; 2005.
36. 3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J. Dermatol. 17:135-142; 1990.
37. 3, TV-02) inhibits phorbol ester-induced epidermal proliferation and cutaneous inflammation, and induces epidermal differentiation in mice. Arch. Dermatol. Res. 288:656-663; 1996.
38. Chou, T. C.; Talalay, P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:207-216; 1981.
39. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55; 1984.
40. Donaldson, K. L.; Goolsby, G. L.; Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer 57:847-855; 1994.